Showing results (311-320 of 407) with videos related to

Sort By:
Pageof 41
BMJ Open|February 14, 2026
Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA)Klaus Krueger, Frank Behrens, Jan Brandt-Juergens, et al.
Rheumatology and Therapy|August 5, 2022
Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized TrialPhilip J Mease, Herbert Kellner, Akimichi Morita, et al.
Clinical and Experimental Rheumatology|September 3, 2016
The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016Kevin L Winthrop, Vibeke Strand, Désiréé M van der Heijde, et al.
Clinical Immunology (Orlando, Fla.)|August 17, 2017
The unmet need in rheumatology: Reports from the targeted therapies meeting 2017Kevin L Winthrop, Vibeke Strand, Désirée van der Heijde, et al.
RMD Open|October 18, 2024
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47Josef S Smolen, Jakub Trefler, Artur Racewicz, et al.
Arthritis Research & Therapy|September 15, 2021
The citrullinated/native index of autoantibodies against hnRNP-DL predicts an individual "window of treatment success" in RA patientsBianka Marklein, Madeleine Jenning, Zoltán Konthur, et al.
Annals of the Rheumatic Diseases|December 2, 2017
Monocyte alterations in rheumatoid arthritis are dominated by preterm release from bone marrow and prominent triggering in the jointBiljana Smiljanovic, Anna Radzikowska, Ewa Kuca-Warnawin, et al.
Annals of the Rheumatic Diseases|February 19, 2017
A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritisGerd R Burmester, Iain B McInnes, Joel Kremer, et al.
Clinical Rheumatology|September 13, 2021
Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52Frank Behrens, Soyi Liu Leage, Christophe Sapin, et al.
Lancet (London, England)|August 25, 2004
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trialMichael E Farkouh, Howard Kirshner, Robert A Harrington, et al.
Pageof 41